Latest News
Viroclinics Biosciences Acquires DDL Diagnostic to Enhance Position in Anti-Viral, Vaccine Testing
Monday 09 March 2020

9 March 2020 - Netherlands-based virology contract research organisation Viroclinics Biosciences has acquired Netherland-based diagnostic solutions provider DDL Diagnostic Laboratory to serve the biopharmaceutical industry with anti-viral and vaccine testing, the company said.

Financial details are not disclosed.

Viroclinics said joining DDL will enhance Viroclinics' l position as a specialised contract research organisation, adding to its service offering, capacity and geographic presence.

Together, the Viroclinics and DDL teams will continue to invest in virology, adjacent and novel therapeutic fields, with the goal of serving a growing global client base.

Viroclinics Biosciences serves the biopharmaceutical community with preclinical, clinical diagnostic, assay development and clinical trial logistics services.

DDL Diagnostic Laboratory is a laboratory specialised in (molecular) diagnostic testing and diagnostic assay development. DDL performs advanced (molecular) diagnostic testing on behalf of pharmaceutical companies and clinical laboratories.
Date Published: 09/03/2020
Target: DDL Diagnostic Laboratory
Country: Netherlands
Sector: Pharmaceuticals
Type: Corporate acquisition
Status: Closed
Buyer: Viroclinics Biosciences
Terms of the deal were not disclosed